Export of US Cigarettes Declines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

WASHINGTON-The number of cigarettes exported annually from the United States has declined by 25%, according to the Agriculture Department. Exports fell from 201.3 billion cigarettes in 1998 to 151.4 billion in 1999.

WASHINGTON—The number of cigarettes exported annually from the United States has declined by 25%, according to the Agriculture Department. Exports fell from 201.3 billion cigarettes in 1998 to 151.4 billion in 1999.

Experts say the decline is due not only to people overseas smoking less, primarily the result of higher prices triggered by tax increases, but also to a shift in the production of cigarettes by the tobacco industry from the United States to other countries.

Articles in this issue
Couric Urges Doctors to Talk to Patients About Colon Cancer
Automated Imaging Notification System Close to Fail-Safe
Higher Dairy Consumption Linked to Prostate Cancer Risk
First-Year Funding of Early Detection Research Network Complete
Gritty Antitobacco Ads and More From Legacy Foundation
Tositumomab Effective for Low-Grade Follicular Lymphoma
New Awards Spotlight Courage of Cancer Survivors
Hospital Volume Shown to Predict Breast Cancer Outcome
New Drug Information Website
NCCN Presents Updated Colorectal Cancer Guidelines
Taxol Teamed With Herceptin Tested Against Prostate Cancer
Adding Paclitaxel to Adjuvant FAC in Operable Breast Cancer May Lower Risk of Recurrence
Trend Toward Improved Outcomes With 5-FU/LV Plus RhuMabVEGF in Colorectal Cancer
Weekly Taxol/Herceptin: 60% RR in Metastatic Breast Cancer
Colonoscopy vs Sigmoidoscopy in Asymptomatic Women
Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

Durvalumab/Radiotherapy May Show Viability in Chemo-Ineligible NSCLC

Roman Fabbricatore
October 17th 2025
Article

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

Russ Conroy
October 16th 2025
Article

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.

Neoadjuvant FOLFIRINOX Shows Comparable Survival vs Chemoradiation in PDAC

Roman Fabbricatore
October 16th 2025
Article

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.

EO2463 combines 4 synthetic peptides that correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with CD20, CD22, CD37, and CD268, the B lymphocyte-specific lineage markers.

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Tim Cortese
October 16th 2025
Article

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.